Prospettive Terapeutiche Future per Il Trattamento Del Cancro Del Colon Retto Avanzato: La Nostra Esperienza Con Oxaliplatino Associato a Fluorofolati in Cronoinfusione
Restricted accessResearch articleFirst published online May, 2000
Prospettive Terapeutiche Future per Il Trattamento Del Cancro Del Colon Retto Avanzato: La Nostra Esperienza Con Oxaliplatino Associato a Fluorofolati in Cronoinfusione
BleibergH.: Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol., 23: 42–50, 1996.
2.
de GramontA., VignoudJ., TournigandC., LouvetC., AndreT., VaretteC., RaymondE., MoreauS., Le BailN., KrulikM.: Oxaliplatin with high-dose leucovorin and 5-FU 48 hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33A: 214–219, 1997.
3.
de GramontA., BossetJ.F., MilanC., RougierP., BoucheO., EtienneP.L., MorvanF., LouvetC., GuillotT., FrancoisE., BedenneL.: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol., 15: 808–815, 1997.
4.
ConnorsT.A., JonesM., RossW., BraddockP.D., KhokharA.R., TobeM.L.: New platinum complexes with anti-tumor activity. Chem. Biol. Interact, 5: 415–424, 1972.
5.
BurchenalJ.H., KalaerK., LokysL.: Studies of cross-resistance, synergistic combination and blocking of activity of platinum derivates. Biochimie, 60: 961–965, 1978.
6.
RixeO., OrtuzarW., AlvaresM., ParkerR., ReedE., PaullK., FojoT.: Oxaliplatin, tetraplatin, cisplatin, and carbo-platin: spectrum of activity in drug-resistant cell lines and in cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol, 52: 1855–1865, 1996.
7.
WeinsteinJ., MeyersT.G., O'ConnorP.M., FriendS.H., FornaceA.J.Jr., KohnK.W., FojoT., BatesS.E., RubinsteinL.V., AndersonN.L., BuolamwiniJ.K., van OsdolW.W., MonksA.P., ScudieroD.A., SausvilleE.A., ZaharevitzD.W., BunowB., ViswanadhanV.N., JohnsonG.S., WittesR.E., PaullK.D.: An information-intensive approach to the molecular pharmacology of cancer. Science, 275: 343–349, 1997.
8.
ScheefE.D., HowellS.B.: Computer modeling of the primary cisplatinum and oxaliplatin DNA adduct and relevance to mismatch repair recognition. Proc. Am. Assoc. Cancer Res., 39: 158a, 1998.
9.
FinkD., NebelS., AebiS.: Effect of loss of DNA mismatch repair on cisplatin, oxaliplatin, and JM216 sensitivity. Proc. Am. Assoc. Cancer Res., 38: 523a, 1997.
10.
FinkD., ZhengH., NebelS.: Resistance to cisplatin not to oxaliplatin in DNA mismatch repair deficient xenografts in athymic nude mice. Proc. Am. Soc. Clin. Oncol., 16: 531a, 1997.
11.
CunninghamJ.M., ChristensenE.R., TesterD.G., KimC.Y., RocheP.C., BurgartL.J., ThibodeauS.N.: Hypermethylation of the hmlhl promoter in colon cancer with microsatellite instability. Cancer Res., 58: 3455–3460, 1998.
12.
ThibodeauS.N., FrenchA.J., CunninghamJ.M., TesterD., BurgartL.J., RocheP.C., McDonnellS.K., SchaidD.J., VockleyC.W., MichelsV.V., FarrG.H.Jr., O'ConnellM.J.: Microsatellite instability in colon rectal cancer: different mutator phenotypes and principal involvement of hMLH1. Cancer Res., 58: 1713–1718, 1998.
13.
ThibodeauS.N., FrenchA.J., RocheP.C., CunninghamJ.M., TesterD.J., LindorN.M., MosleinG., BakerS.M., LiskayR.M., BurgartL.J., HonchelR., HailingK.C.: Altered expression of hMSH2 and hMSH 1 in tumor with microsatellite instability and genetic alteration in mismatch repair genes. Cancer Res., 56: 4836–4840, 1996.
14.
HermanJ.G., UmarA., PolyacK., GraffJ.R., AhujaN., IssaJ.P., MarkowitzS., WillsonJ.K., HamiltonS.R., KinzlerK.W., KaneM.F., KolodnerR.D., VogelsteinB., KunkelT.A., BaylinS.B.: Incidence and functional consequence of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA95: 6870–6875, 1998.
15.
RaymondE., DjelloulS., Bouquet-FagotC.: Oxaliplatin and cisplatin in combination with 5fu, specific thymidilate synthase inhibitor (ag337, zd1694), and topoisomerase I inhibitor (sn38, cpt11), in human colonic, ovarian and breast cancer. Proc. Am. Assoc. Cancer Res., 37: 291a, 1996.
16.
Maindrault-GoebelF., De GramontA., LouvetC.: Bimonthly oxaliplatin with leucovorin and 5FU in pretreated metastatic colorectal cancer (FOLFOX 6). Proc. Am. Soc. Clin. Oncol., 17: 273a, 1998.
17.
de GramontA., LouvetC., AndrèT., TournigandC., KrulikM.: A review of GERCOD trials of bimonthly leucovorin plus 5FU 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sue les Cancer de l'Ovaire et Digestif (GERCOD). Eur. J. Cancer, 34: 619–626, 1998.
18.
Maindrault-GoebelF., de GramontA., LouvetC.: High-dose oxaliplatin with the simplified 48h bimonthly leucovorin and 5FU regimen in pretreated metastatic colorectal cancer (FOLFOX). Proc. Am. Soc. Clin. Oncol., 18: 265a, 1999.
19.
BuecheleT., SchoeberC., KroeningH.: Weekly high-dose 5FU and folinic acid with addition of oxaliplatin after documented progression under high-dose infusional 5FU/FA in patients with advanced colorectal cancer: a preliminary report. Proc. Am. Soc. Oncol., 17: 287a, 1998.
20.
GamelinE., Le BouilA., Boisdron CelleM., TurcantA., DelvaR., CailleuxA., KrikorianA., BrienzaS., CvitkovicE., RobertJ., LarraF., AllainP.: Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5FU in colorectal cancer patients. Clin. Cancer Res., 3: 891–899, 1997.
21.
BismuthH., AdamR.: Reduction of non resectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin. Oncol., 25: 40–46, 1998.
22.
BismuthH., AdamR., LeviF., FarabosC., WaechterF., CastaingD., MajnoP., EngerranL.: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg., 224: 509–520, 1996.
23.
LeviF., MissetJ.L., BrienzaS., AdamR., MetzgerG., ItzakhiM., CaussanelJ.P., KunstlingerF., LecouturierS., Descorps-DeclereA.: A cronopharmacologic phase II clinical trial with 5FU folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer, 69: 893–900, 1992.
24.
LeviF., DogliottiL., PerpointB.: A multicenter phase II trial of intensified chronotherapy with oxaliplatin, 5FU and folinic acid in patients with previously untreated metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 16: 2'66a, 1997.
25.
LeviF., ZidaniR., MissetJ.L.: Randomised multicentre trial chronoterapy with oxaliplatin, 5FU and folinic acid in metastatic colorectal cancer. Lancet, 350: 681–686, 1997.
26.
LeviF., ZidaniR., VannetzelJ.M., PerpointB., FocanC., FaggiuoloR., CholletP., GarufiC., ItzhakiM., DogliottiL.: Chronomodulated versus fixed infusion rated delivery of ambulatory chemotherapy with oxaliplatin, 5FU and folinic acid in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst., 86: 1608–1617, 1994.
27.
WassermanE., CuvierC., LokiecF., GoldwasserF., KallaS., Mery-MignardD., OuldkaciM., BesmaineA., Dupont-AndreG., MahjoubiM., MartyM., MissetJ.L., CvitkovicE.: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: result of two independent phase I studies with pharmacokinetics. J. Clin. Oncol., 17: 1751–1759, 1999.
28.
Zeghari-SqualliN., MissetJ.L., CvitkovicE.: Mechanism of irinotecan in vitro synergism between SN38 and oxaliplatin. Proc. Am. Assoc. Cancer Res., 38: 3 (abstr), 1997.
